Showing 1 - 4 results of 4 for search 'R Wäsch', query time: 0.02s Refine Results
  1. 1
    S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS

    S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS by P. Rodriguez Otero, A. D’Souza, D. Reece, N. W. van de Donk, A. Chari, A. Krishnan, T. Martin, M. V. Mateos, D. Morillo, D. Hurd, L. Rosinol, A. S. Balari, R. Wäsch, D. Vishwamitra, S. X. Wang Lin, T. Prior, L. Vandenberk, M.-A. D. Smit, A. Oriol, B. Dholaria

    Published 2022-06-01
    Get full text
    Article
  2. 2
    B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

    B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY by P Rodriguez-Otero, B Dholaria, E Askari, D Reece, N van de Donk, A Chari, H Goldschmidt, A Krishnan, T Martin, M Mateos, D Morillo, C Rodriguez, L Rosinol, J San-Miguel, A Balari, R Wäsch, K Weisel, R Verona, S Lin, T Prior, M Wade, B Weiss, J Goldberg, A Oriol, P Hari

    Published 2022-04-01
    Get full text
    Article
  3. 3
    S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB

    S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN CO... by N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, A. Chari

    Published 2022-06-01
    Get full text
    Article
  4. 4
    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG

    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP,... by M. Lübbert, P. Wijermans, M. Kicinski, S. Chantepie, W. van der Velden, R. Noppeney, L. Griskevicius, A. Neubauer, M. Crysandt, R. Vrhovac, M. Luppi, S. Fuhrmann, E. Audisio, A. Candoni, O. Legrand, R. Foà, G. Gaidano, D. van Lammeren-Venema, E. F. Posthuma, M. Hoogendoorn, A. Giraut, M. Stevens-Kroef, J. H. Jansen, E. Ammatuna, J.-P. Vilque, R. Wäsch, H. Becker, N. Blijlevens, U. Dührsen, F. Baron, S. Suciu, S. Amadori, A. Venditti, G. Huls

    Published 2022-06-01
    Get full text
    Article

Search Tools: